由YAP介导的巨细胞极化与动脉样硬化的进展有关
Xin Zhang1, Xia Sun2, Qiaohong Qin1
1Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, Shaanxi, 710021, China.
European journal of pharmacology
|November 7, 2025
概括
是的相关蛋白 (YAP) 通过通过CD36上调调节驱动M1巨细胞极化来促进动脉样硬化. 在巨细胞中抑制YAP为动脉样硬化提供了潜在的治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 免疫学 免疫学 免疫学
- 分子医学是分子医学.
背景情况:
- 大细胞两极分化是动脉样硬化发展的关键因素.
- 是的相关蛋白 (YAP) 影响巨细胞极化,但其在动脉样硬化中的特定作用尚未完全理解.
研究的目的:
- 为了研究YAP介导的巨细胞极化在动脉样硬化中的作用.
- 探索YAP作为动脉样硬化的潜在治疗点.
主要方法:
- 在使用高胆固醇饮食和AAV8-mPCSK9注射的小鼠中诱导动脉样硬化.
- 使用具有巨细胞特异性YAP删除 (YAPΔM) 的小鼠和ApoE-/-小鼠.
- 在巨细胞中以腺相关病毒 (AAV) 为媒介的针对YAP的shRNA的传递被用于治疗评估.
主要成果:
- 宏细胞特异性YAP删除减少了动脉样硬化斑块的大小,并促进了M2宏细胞的两极分化.
- YAP过度表达逆转了这些影响,表明YAP促进动脉样硬化.
- YAP通过TEAD4上调了CD36的表达,增强了氧化低密度脂蛋白 (ox-LDL) 的吸收和M1极化.
- 在ApoE-/-小鼠中,巨细胞特异性YAP敲除显著减轻了动脉样硬化.
结论:
- 通过通过TEAD4通过CD36上调调节诱导M1巨分极,YAP促进动脉样硬化.
- 在巨细胞中准YAP为动脉样硬化治疗提供了一个有希望的治疗途径.
关键词:
动脉样硬化是一种动脉样硬化.CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36巨细胞是一个巨细胞.是的 - 相关蛋白质.更多相关视频
07:46Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
25.9K
07:45Metabolic Characterization of Polarized M1 and M2 Bone Marrow-derived Macrophages Using Real-time Extracellular Flux Analysis
Published on: November 28, 2015
36.4K
相关概念视频
01:38Inflammation
61.5K
Overview
61.5K
01:30Atherosclerosis I: Introduction
853
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
853
01:26Coronary Artery Disease II: Pathophysiology
355
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
355
01:30Peripheral Artery Disease I: Introduction
295
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
295
01:26Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307